Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan L Epstein

Showing results (51-60 of 98) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapyRebecca E Sadun, Suzanne M Sachsman, Xiaoying Chen, et al.
International Journal of Molecular Sciences|December 21, 2017
Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell LymphomaLong Zheng, Peisheng Hu, Brandon Wolfe, et al.
Scientific Reports|January 4, 2017
Soluble OX40L and JAG1 Induce Selective Proliferation of Functional Regulatory T-Cells Independent of canonical TCR signalingPrabhakaran Kumar, Khaled Alharshawi, Palash Bhattacharya, et al.
Cancer|March 23, 2011
Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entityMelissa G Lechner, Stephen Lade, Daniel J Liebertz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 18, 2019
Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer ImmunotherapyXiaojing Shi, Qinqin Cheng, Tianling Hou, et al.
Molecular Cancer Therapeutics|October 17, 2013
Cytoreductive chemotherapy improves the biodistribution of antibodies directed against tumor necrosis in murine solid tumor modelsJulie K Jang, Leslie A Khawli, Ryan Park, et al.
Head & Neck Oncology|February 24, 2010
Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1Daniel J Liebertz, Melissa G Lechner, Rizwan Masood, et al.
Scientific Reports|July 28, 2017
PKC-ѳ is dispensable for OX40L-induced TCR-independent Treg proliferation but contributes by enabling IL-2 production from effector T-cellsKhaled Alharshawi, Alejandra Marinelarena, Prabhakaran Kumar, et al.
Expert Review of Anticancer Therapy|August 27, 2014
Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNARuth A Bryan, Zewei Jiang, Thomas Jandl, et al.
Journal for Immunotherapy of Cancer|February 18, 2016
Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvantBrian M Andersen, Junzhe Xia, Alan L Epstein, et al.
Pageof 10

Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapyRebecca E Sadun, Suzanne M Sachsman, Xiaoying Chen, et al.
International Journal of Molecular Sciences|December 21, 2017
Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell LymphomaLong Zheng, Peisheng Hu, Brandon Wolfe, et al.
Scientific Reports|January 4, 2017
Soluble OX40L and JAG1 Induce Selective Proliferation of Functional Regulatory T-Cells Independent of canonical TCR signalingPrabhakaran Kumar, Khaled Alharshawi, Palash Bhattacharya, et al.
Cancer|March 23, 2011
Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entityMelissa G Lechner, Stephen Lade, Daniel J Liebertz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 18, 2019
Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer ImmunotherapyXiaojing Shi, Qinqin Cheng, Tianling Hou, et al.
Molecular Cancer Therapeutics|October 17, 2013
Cytoreductive chemotherapy improves the biodistribution of antibodies directed against tumor necrosis in murine solid tumor modelsJulie K Jang, Leslie A Khawli, Ryan Park, et al.
Head & Neck Oncology|February 24, 2010
Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1Daniel J Liebertz, Melissa G Lechner, Rizwan Masood, et al.
Scientific Reports|July 28, 2017
PKC-ѳ is dispensable for OX40L-induced TCR-independent Treg proliferation but contributes by enabling IL-2 production from effector T-cellsKhaled Alharshawi, Alejandra Marinelarena, Prabhakaran Kumar, et al.
Expert Review of Anticancer Therapy|August 27, 2014
Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNARuth A Bryan, Zewei Jiang, Thomas Jandl, et al.
Journal for Immunotherapy of Cancer|February 18, 2016
Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvantBrian M Andersen, Junzhe Xia, Alan L Epstein, et al.
Pageof 10